Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | EBP | Q15125 | 1/20 | 0.47 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3235228 | 1.00 | CYP2D6 (0.59) | CYP2D6CYP1A2PKMALDH1A1KDM4E | |
| SCHEMBL3235232 | 1.00 | CYP2D6 (0.59) | CYP2D6CYP1A2PKMALDH1A1KDM4E | |
| SCHEMBL8425188 | 0.92 | ALDH1A1 (0.56) | CYP2D6CYP1A2PKMALDH1A1KDM4E | |
| SCHEMBL6881853 | 0.92 | ALDH1A1 (0.56) | CYP2D6CYP1A2PKMALDH1A1KDM4E | |
| SCHEMBL8879797 | 0.91 | CYP2D6 (0.66) | CYP2D6CYP1A2PKMALDH1A1KDM4E | |
| SCHEMBL841102 | 0.89 | DHCR7 (0.53) | CYP2D6CYP1A2KMT2AMEN1MAPT | |
| SCHEMBL20594955 | 0.89 | CYP2D6 (0.59) | CYP2D6CYP1A2PKMALDH1A1KDM4E | |
| SCHEMBL7466566 | 0.86 | ALDH1A1 (0.49) | CYP2D6CYP1A2PKMALDH1A1KDM4E | |
| SCHEMBL24479773 | 0.85 | HSD11B1 (0.54) | PKMALDH1A1KDM4EPOLBHTT | |
| SCHEMBL420300 | 0.82 | CYP2D6 (0.74) | CYP2D6CYP1A2PKMPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058454-B2 | Method for preparing 1,3-disubstituted pyrrolidine compounds | MEDICHEM, S.A. (ES) | 2011-11-15 | — | — | US | disclosed |
| WO-2011106650-A2 | NOVEL P53-MDM2/P53-MDM4 ANTAGONISTS TO TREAT PROLIFERATIVE DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-09-01 | — | — | WO | disclosed |
| US-20090306406-A1 | METHOD FOR PREPARING 1,3-DISUBSTITUTED PYRROLIDINE COMPOUNDS | MEDICHEM ,S.A. (ES) | 2009-12-10 | — | — | US | disclosed |
| US-20080269505-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-10-30 | — | — | US | disclosed |
| EP-1278728-B1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2004-08-25 | — | — | EP | disclosed |
| EP-1278728-A1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-29 | — | — | EP | disclosed |
| US-6451819-B2 | PYRROLIDINE-3-YL-SULFANYL, OR SUFONYL OR SUFINYL DERIVATIVES USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | HOFFMANN-LA ROCHE INC. | 2002-09-17 | — | — | US | disclosed |
| US-20010047031-A1 | Heterocyclic compounds useful as NMDA receptor selective subtype blockers | HOFFMANN-LA ROCHE INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001081303-A1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREAMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-01 | — | — | WO | disclosed |
| EP-0505377-B1 | MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LTD (GB) | 1996-01-03 | — | — | EP | disclosed |
| EP-0505376-B1 | MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LTD (GB) | 1994-12-07 | — | — | EP | disclosed |
| US-5340831-A | Muscarinic receptor antagonists | PFIZER INC. (US) | 1994-08-23 | — | — | US | disclosed |
| US-5281601-A | Imide substituted indoline derivatives | PFIZER INC. (US) | 1994-01-25 | — | — | US | disclosed |
| EP-0388054-B1 | Pyrrolidine derivatives | PFIZER LTD (GB) | 1993-11-03 | — | — | EP | disclosed |
| US-5233053-A | Pyrrolidine derivatives | PFIZER INC. (US) | 1993-08-03 | — | — | US | disclosed |
| EP-0505376-A1 | MUSCARINIC RECEPTOR ANTAGONISTS. | PFIZER LTD (GB) | 1992-09-30 | — | — | EP | disclosed |
| US-5096890-A | PYRROLIDINE DERIVATIVES | PFIZER INC. (US) | 1992-03-17 | — | — | US | disclosed |
| WO-1991009015-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 1991-06-27 | — | — | WO | disclosed |
| WO-1991009013-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 1991-06-27 | — | — | WO | disclosed |
| EP-0388054-A1 | Pyrrolidine derivatives | Pfizer Limited (GB) | 1990-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269505-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | CYP2D6 329/4885CYP1A2 2087/4885PKM 4425/4885 |
| US-20090306406-A1 | METHOD FOR PREPARING 1,3-DISUBSTITUTED PYRROLIDINE COMPOUNDS | OPRL1, OPRK1, OPRD1 | CYP2D6 556/4885CYP1A2 1059/4885PKM 2477/4885 |
| US-20010047031-A1 | Heterocyclic compounds useful as NMDA receptor selective subtype blockers | GRIN1, GRM1, GRIN2B | CYP2D6 1038/4885CYP1A2 1970/4885PKM 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.